Table 2.
The risk of all-grade myocardial infarction, heart failure, pericardial diseases, embolism, thrombosis and vasculis: subgroup analyses were carried out based on PD-1/PD-L1.
| Treatment regimen | PD-1/PD-L1+chemotherapy VS chemotherapy | PD-1/PD-L1 VS chemotherapy | PD-1/PD-L1 VS placebo | |
|---|---|---|---|---|
| myocardial infraction | PD-1 | OR=0.69, 95% CI [0.11, 4.40], p=0.70 | OR=0.80, 95% CI [0.20, 3.29], p=0.76 | OR=2.16, 95% CI [0.46, 10.09], p=0.33 |
| PD-L1 | OR=0.86, 95% CI [0.32, 2.32], p=0.77 | OR=0.92, 95% CI [0.10, 8.91], p=0.95 | OR=1.91, 95% CI [0.32, 11.36], p=0.48 | |
| heart failure | PD-1 |
OR=1.43, 95% CI [0.33, 6.26], p=0.64 |
OR=0.72, 95% CI [0.16, 3.24], p=0.67 |
OR=2.04, 95% CI [0.18, 22.54], p=0.56 |
| PD-L1 | OR=1.17, 95% CI [0.52, 2.63], p=0.70 | OR=0.56, 95% CI [0.13, 2.30], p=0.42 | OR=3.22, 95% CI [0.37, 28.43], p=0.29 | |
| pericardial diseases | PD-1 |
OR=0.96, 95% CI [0.06, 15.55], p=0.98 |
N/A |
OR=3.82, 95% CI [0.44, 33.23], p=0.22 |
| PD-L1 | OR=2.42, 95% CI [0.46, 12.82], p=0.03 | N/A | OR=2.48, 95% CI [0.12, 51.79], p=0.56 | |
| emobolism | PD-1 |
OR=1.17, 95% CI [0.33, 4.13], p=0.81 |
OR=1.28, 95% CI [0.15, 10.61], p=0.82 |
OR=1.37, 95% CI [0.09, 19.88], p=0.82 |
| PD-L1 | OR=1.05, 95% CI [0.66, 1.66], p=0.85 | OR=1.49, 95% CI [0.18, 12.17], p=0.71 | OR=1.03, 95% CI [0.26, 4.01], p=0.97 | |
| thrombosis | PD-1 |
OR=0.67, 95% CI [0.15, 2.98], p=0.60 |
OR=0.96, 95% CI [0.29, 3.15], p=0.95 |
OR=0.54, 95% CI [0.09, 3.47], p=0.52 |
| PD-L1 | OR=1.74, 95% CI [0.79, 3.84], p=0.17 | OR=0.18, 95% CI [0.01, 3.77], p=0.27 | OR=0.58, 95% CI [0.12, 2.73], p=0.49 | |
| vasculitis | PD-1 |
OR=0.80, 95% CI [0.20, 3.29], p=0.76 |
OR=0.32, 95% CI [0.01, 7.89], p=0.49 |
OR=5.07, 95% CI [0.24, 105.95], p=0.30 |
| PD-L1 | OR=0.80, 95% CI [0.20, 3.29], p=0.76 | OR=0.83, 95% CI [0.17, 4.01], p=0.81 | OR=1.02, 95% CI [0.24, 4.43], p=0.98 |
PD-1, Programmed cell death 1; PD-L1, Programmed cell death 1 ligand 1; OR, Odds Ratio; CI, Confidence Interval; N/A, not available.